During the third quarter of 2018, we opened a Phase I/II randomized, double blinded, placebo-controlled trial to evaluate the safety and efficacy of Coversin in patients with the inflammatory mediated eye disorder Atopic Keratoconjunctivitis (AKC).
Results in a rodent model of Experimental Immune Conjunctivitis (EIC), undertaken at Moorfields Hospital Institute of Ophthalmology, showed that Coversin demonstrated significant anti-inflammatory activity. In this preclinical model of severe eye surface inflammation, Coversin, applied topically, resulted in a statistically significant reduction (64%, p<0.001) in late phase inflammation versus placebo.
We continue to develop Coversin in indications that take advantage of the dual-acting properties of the drug to inhibit both C5 and LTB4.
